impact of prior bendamustine exposure on bsab treatment outcomes in patients with b-cell lymphoma
Published 8 months ago • 130 plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
4:33
brawm: bendamustine, rituximab and acalabrutinib for waldenström’s macroglobulinemia
-
2:19
gemcitabine and bendamustine as a salvage regimen for recurrent/refractory hodgkin lymphoma
-
3:53
standard-of-care setting results of axi-cel in r/r large b-cell lymphoma
-
2:53
autohct in dlbcl in the car-t era
-
3:35
epigenomics in precision oncology
-
28:08
dr. gaby hobbs, md: diagnosis and initial treatment options for et, pv & mf
-
12:52
the future of precision oncology
-
2:38
car-t therapy for aggressive b-cell lymphomas
-
3:04
applying molecular understanding of dlbcl to management strategies
-
7:16
changes in the classification of dlbcl
-
2:17
the impact of checkpoint inhibitor-based salvage regimens in patients with r/r hl undergoing autosct
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
1:51
checkpoint inhibition in the treatment of mpns
-
0:45
difference between quality of life & patient-reported outcomes
-
2:31
relevance trial analysis: investigating the impact of lymphocyte/monocyte ratio on patient outcomes
-
1:28
phase i study of pevonedistat and ibrutinib in r/r b-nhl
-
2:02
targeting the survival cascade of b-cells in lymphoid malignancies
-
2:41
an overview of the latest advances in hematology
-
0:53
go-flag: bridge therapy to allo-sct in r/r aml